MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

Home » Zimmer slides on Q1 results | Earnings Roundup

Zimmer slides on Q1 results | Earnings Roundup

By

MassDevice.com Earnings Roundup

Investors sent shares of Zimmer (NYSE:ZMH) down 5% this morning in pre-market trading after the orthopedic device maker reported sales and earnings in-line with Wall Street’s expectations, but lackluster sales of hip and knee implants.

The Warsaw, Ind.-based company posted profits of $209.6 million, or $1.17 per diluted share, on sales of $1.14 billion for the 3 months ended March 31.

That’s a bottom-line gain of less than 1% and a top-line addition of 2.2%, compared with profits of $208.9 million, or $1.08 diluted EPS, on sales of $1.12 billion during Q1 2011. Diluted EPS rose 8.3% year-over-year.

"Zimmer delivered year-over-year sales growth in all geographic segments and in most product categories in the quarter," president & CEO David Dvorak said in prepared remarks. "Looking forward, our new product introductions and progress in our transformation programs will enable the Company to generate increased value to stockholders."

Overall sales of joint reconstruction products rose 2% to $860 million, with most of that growth coming from the Asia-Pacific region. U.S. recon sales growth was flat, as were the revenue figures for domestic sales of knee and hip implants, at $468 million, $279 million and $154 million, respectively.

"We think some may be a bit disappointed that US hip/knee growth did not show as much of a sequential y/y growth acceleration this quarter as some may have been expecting, especially in knees,” wrote Leerink Swann analyst Richard Newitter in a note to investors this morning. “This reinforces our view that US ortho recon markets have likely bottomed and remain stable, possibly even beginning to show some early signs of improvement. However, we still think it’s too early to call an inflection point for a procedure volume recovery.”

Zimmer lowered its 2012 sales guidance to growth of between 0% and 2.5%, saying it expects foreign exchange rates to cut the top line by between 1.5% and 2%. Its prior guidance predicted FX to cut about 1% from revenues.

Diluted EPS are forecast to run between $4.70 and $4.90, down from $4.75 to $4.95.

ZMH shares opened today at $61.20, down 3.5% from yesterday’s $63.43 close. Shares were trading up slightly at $61.35 as of about 9:45 this morning.

 Second-quarter profits slide 24% for Hill-Rom
Hill-Rom Holdings (NYSE:HRC) posted profits of $25.3 million, or 40¢ per diluted share, on sales of $415.1 million for the 3 months ended March 31.

That compares with profits of $33.1 million, or 52¢ per diluted share, on sales of $402.1 million during the same period last year.
Read more

 Merit Medical’s Q1 profits slide despite sales increase
Merit Medical (NSDQ:MMSI) posted profits of $5.7 million, or 14¢ per diluted share, on sales of $95.6 million for the 3 months ended March 31.

That compares with profits of $6.6 million, or 18¢ per diluted share, on sales of $86.6 million during the same period last year.
Read more

 Sales plunge, losses tick up for NeuroMetrix during Q1
NeuroMetrix (NSDQ:NURO) posted losses of $2.8 million, or 33¢ per share, on sales of $2.1 million for the 3 months ended March 31.

That compares with losses of $2.7 million, or 70¢ per share, on sales of $2.9 million during the same period last year.
Read more

 Palomar’s Q1 losses soar 21% on slow sales growth
Palomar Medical (NSDQ:PMTI) posted losses of $2.3 million, or 12¢ per share, on sales of $19.0 million for the 3 months ended March 31.

That compares with losses of $1.9 million, or 10¢ per share, on sales of $18.2 million during the same period last year.
Read more

 Shire’s DermaGraft sales stay flat
British biotech Shire (NSDQ:SHPGY) said it sold $48.8 million worth of the Dermagraft skin substitute during the 1st quarter. Since Q3 2011, Shire’s reeled in about $143.4 million from the regenerative medicine product ($50 million in Q3 2011, $55 million in Q4 and the $48.8 million logged in Q1 2012).

Overall, Shire posted profits of $238.4 million, or 41¢ per diluted share, on sales of $1.17 billion for the 3 months ended March 31.

That compares with profits of $211.3 million, or 37¢ per diluted share, on sales of $972.2 million during the same period last year.
Read more

 Sorin’s Q1 profits slide
Sorin Group (BIT:SRN) posted profits of $15 million (€191.7M) on sales of $272 million (€191.7M) for the 3 months ended March 31.

That compares with profits of $18 million (€10.6M) on sales of $259 million (€182.3M) during the same period last year.
Read more

 Varian Medical’s Q2 sales, earnings rise
Varian Medical (NYSE:VAR) posted profits of $107.8 million, or 94¢ per diluted share, on sales of $720.3 million for the 3 months ended March 31.

That compares with profits of $103.1 million, or 86¢ per diluted share, on sales of $648.4 million during the same period last year.
Read more

More medical device sales and earnings from MassDevice.com

In case you missed it

RSS From Medical Design & Outsourcing

  • Plastics and medical devices: Changes for safety and cost
    The move toward polypropylene and polyethylene in medical devices requires new manufacturing and assembly solutions such as ultrasonic and laser welding. Didier Perret, Emerson Plastics are ubiquitous in medical applications thanks to their light weight, durability and flexibility, among other attributes. However, concern has been increasing in recent years about the possible negative effects of… […]
  • Medtronic’s recall of HawkOne system is Class I
    The FDA today issued a notice confirming that the recall of Medtronic’s (NYSE:MDT) HawkOne system is Class I, the most serious kind. So far in 2022, the FDA has classified three Medtronic-related recalls as Class I, with the Covidien (part of Medtronic) Puritan Bennett 980 series ventilator and the Synergy Cranial and StealthStation S7 Cranial software receiving the same classification earlier… […]
  • January 2022 Issue: The pandemic tested Metronic’s mettle
      The pandemic tested Medtronic’s mettle: Its CFO explains how How Abbott seeks to improve care, health inequities for people with cardiovascular disease Medtech’s biggest personnel changes in 2021 The top 5 medtech news stories of 2021 Some thoughts for medtech leaders in 2022 Starting our third year of the COVID-19 pandemic, I wonder when… […]
  • Feinstein Institutes researchers develop tiny implantable neurostimulator for mouse studies
    Researchers have developed a novel, fully implantable wireless bidirectional vagus nerve stimulation (VNS) and sensing device for mice. Engineers and researchers at the Institute of Bioelectronic Medicine at The Feinstein Institutes for Medical Research published details about the device and its capabilities in Biosensors and Bioelectronics. They think the device has the potential to transform how… […]
  • MIT team working on all-in-one diabetes management devices
    MIT researchers are touting a platform aimed at helping patients maintain healthy glucose levels by streamlining the diabetes management process. The MIT researchers say it’s hard for people with diabetes to maintain a treatment regimen. Typically at every meal, they need to estimate carbohydrate content, draw blood to measure blood glucose levels, and calculate the… […]
  • Element expands life sciences testing business with pharma, biotech capabilities
    Element Materials Technology recently announced that with the completed acquisition of JMI Laboratories in 2021, it has built out its life sciences testing capabilities for the pharmaceutical and biopharmaceutical industries. The acquisition added more than 1,000 experts in 23 facilities in North America and Europe and marked a strategic shift for the London-based company to… […]
  • Team Technologies acquires consumable medical device manufacturer iiMed
    Team Technologies recently announced that it acquired consumable medical device manufacturer iiMed Medical Solutions for an undisclosed amount. The acquisition is the fourth purchase since Clearlake Capital Group invested in the company in 2018. It is the eighth transaction completed by the company since 2012. Nearshore specialty manufacturer iiMed makes FDA Class I and Class… […]
  • P-Duke Technology is selling dc/dc converters for medical
    P-Duke Technology is promoting its MPS and MPH series of medical dc/dc converters. The MPS and MPH series comply with Medical EN60601-1 and I.T.E. EN 62368-1 certifications, according to the company. They provide 2W and 3.5W output power, 2:1 input range, regulated 5, 9, 12, 15, 24, ±12, ±15 VDC output voltage, and both DIP16… […]
  • Philips backing efforts to reduce CIED infections
    Royal Philips (NYSE:PHG) announced today that it supports the American Heart Association’s efforts to reduce CIED infections. Amsterdam-based Philips offered its support to the initiative to generate awareness among cross-disciplinary specialties and improve survival rates from CIED (cardiovascular implantable electronic device) infections. The company said in a news release that, with its support, the American… […]
  • Democratic senator wants COVID-19 test-makers to lower prices
    Sen. Ed Markey, D-Massachusetts, has sent letters to CEOs of at-home COVID-19 test-makers, asking why tests are selling for as much as $12 apiece. In a letter sent today to Abbott CEO Robert Ford, for example, Markey cited a Reuters story from October 2021 in which British test-maker Mologic said that rapid antigen tests can… […]
  • These medtech companies care a lot about research
    They’re making glaucoma-treating stents, tumor-treating fields, coin-sized CGMs and more. Discover the medtech companies that spend the most on research as a percentage of revenue. The list comes from our annual Big 100 report, which examines the world’s 100 largest medical device companies and ranks them by revenue. (Check out our full Big 100 report… […]

Leave a Reply